SummaryProton beam therapy is a promising treatment option for sinonasal tumors. We report the outcomes of 69 patients with sinonasal tumors treated with proton beam therapy on the multi-institutional Proton Collaborative Group registry study. This is one of the largest series of sinonasal tumors treated with proton beam therapy. Our findings suggest that proton beam therapy is a safe and efficacious treatment option for patients with sinonasal tumors.

Introduction {#sec1}
============

Sinonasal tumors originate from the nasal cavity and paranasal sinuses. The incidence of sinonasal tumors is 0.556 cases per 100,000 population per year, and they often occur in the sixth decade of life with a male predominance of 1.8:1.[@bib1] Overall, they represent approximately 3% to 5% of all head and neck cancers.[@bib2] Sinonasal tumors are a heterogenous group of histologic subtypes, including squamous cell carcinoma (most common), adenocarcinoma, adenoid cystic carcinoma, melanoma, esthesioneuroblastoma, and undifferentiated carcinoma.[@bib3] Diagnosis of sinonasal tumors is complex; it is often delayed owing to a lack of specific clinical symptoms. Thus, sinonasal tumors often present as locally advanced disease with extensive invasion into adjacent normal structures. In these patients, identifying the site of origin can be challenging.[@bib2]

Because sinonasal tumors are rare, there have been no randomized clinical trials to guide treatment recommendations. Current treatment recommendations are based on retrospective, single-institution experiences.[@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10] These studies often include various primary sites, histologic subtypes, and surgical approaches. The heterogeneity of sinonasal malignancies and multiple treatment approaches make it challenging to draw conclusions regarding treatment outcomes.

Achieving local control in sinonasal tumors is both critical and challenging owing to their intimate anatomic relationship with many vital structures such as the brainstem, brain, optic tracts, and eyes.[@bib11] In general, the less common presentation of early stage sinonasal tumors is managed with surgery alone. Locally advanced sinonasal tumors are most commonly managed with multimodality therapy including surgery, radiation therapy (RT), or chemotherapy.[@bib12] In addition, RT can be used as a definitive treatment for patients with unresectable disease or who are otherwise nonsurgical candidates. Historically, treatment outcomes for sinonasal tumors have been poor, with 5-year overall survival rates in the range of 22% to 79%[@bib12] and local control (LC) rates of 40% to 60%.[@bib5], [@bib8], [@bib9], [@bib13] With the advent of modern radiation techniques such as intensity-modulated radiation therapy (IMRT) and charged particle therapy, improved outcomes can potentially be achieved in sinonasal tumors.[@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19]

One of the limitations of conventional photon radiation therapy is the limited ability to safely deliver adequate dose to the primary target without compromising surrounding healthy structures.[@bib15], [@bib16], [@bib19] Charged particle therapy in the form of proton beam therapy (PBT) has clear dosimetric advantages over conventional photon RT. This includes a rapid fall-off dose beyond the Bragg peak and a higher relative biologic effectiveness; these advantages allow the treating radiation oncologist to escalate dose to the primary target and maximally spare adjacent healthy structures.[@bib19] The theoretical advantages of PBT have been suggested to be associated with better outcomes in patients with sinonasal tumors compared with patients treated with conventional photon therapy.[@bib16], [@bib20] In a meta-analysis of nasal cavity and paranasal sinus tumors treated with radiation therapy, Patel et al reported significantly improved locoregional control for PBT than for IMRT.[@bib16] There is a need to report more outcomes associated with PBT for sinonasal tumors because most reports are smaller series from single institutions. The aim of our study is to report the outcomes of patients with sinonasal tumors treated with PBT in the multi-institutional Proton Collaborative Group (PCG) registry study.

Methods and Materials {#sec2}
=====================

The PCG is a nonprofit organization of radiation oncologists including 10 institutions with PBT and 12 treatment sites. Participating institutions for this study include the Northwestern Medicine Chicago Proton Center, ProCure Proton Therapy Center New Jersey, ProCure Proton Therapy Center Oklahoma City, Seattle Cancer Care Alliance Proton Therapy Center, University of Maryland Proton Treatment Center, California Protons Cancer Therapy Center, and Willis-Knighton Cancer Center. This study is an institutional review board--approved analysis of the multi-institutional PCG data registry of patients treated with PBT. Between 2010 and 2016, 69 patients with sinonasal tumors were treated with curative intent PBT on the PCG registry study. Patient demographics and characteristics are listed in [Table 1](#tbl1){ref-type="table"}.Table 1Patient and treatment characteristics (*n =* 69)CharacteristicDe novo irradiation (*n =* 42) no. patients (%)Reirradiation (*n =* 27) no. patients (%)Age (y) Median55.958.1 Range15.7-82.131.3-88.0Sex Male29 (69.0%)17 (63.9%) Female13 (31.0%)10 (37.0%)ECOG PS 030 (71.4%)19 (70.4%) ≥112 (28.6%)8 (29.6%)Smoking status Nonsmoker26 (64.3%)14 (51.9%) Former/current smoker15 (35.7%)13 (48.1%)Primary site Nasal cavity21 (55.3%)14 (60.9%) Maxillary sinus10 (26.3%)5 (21.7%) Ethmoid sinus7 (18.4%)3 (13.0%) Sphenoid sinus01 (4.3%) Not specified44Histology Squamous cell carcinoma15 (35.7%)11 (40.7%) Adenoid cystic carcinoma8 (19.0%)6 (22.2%) Esthesioneuroblastoma10 (23.8%)4 (14.8%) Adenocarcinoma5 (11.9%)4 (14.8%) Small cell neuroendocrine2 (4.8%)1 (3.7%) SNUC2 (4.8%)1 (3.7%)T stage T15 (11.9%)0 T26 (14.3%)3 (11.1%) T36 (14.3%)7 (25.9%) T4a7 (16.7%)9 (33.3%) T4b18 (42.9%)8 (29.6%)N stage N037 (88.1%)19 (70.4%) N1-N25 (11.9%)8 (29.6%)Stage I5 (11.9%)0 II6 (14.3%)2 (7.4%) III6 (14.3%)6 (22.2%) IVA7 (16.7%)11 (40.7%) IVB16 (38.1%)8 (29.6%) IVC2 (4.8%)0Proton beam therapy target Primary site/surgical bed39 (92.9%)23 (92.0%) Primary site + neck2 (4.8%)2 (8.0%) Not specified12Concurrent chemotherapy Yes16 (38.1%)10 (37.0%) No26 (61.9%)17 (63.0%)[^2]

At the time of initial diagnosis, all patients underwent a complete history and physical exam including a flexible nasopharyngolaryngoscopy. All patients received computed tomography (CT) or magnetic resonance imaging (MRI). Positron emission tomography scans were performed at the discretion of the treating physician. A biopsy was obtained in all patients. Tumor staging was based on the seventh edition of the American Joint Committee on Cancer staging system.

All patients were treated supine with a custom thermoplastic immobilization device. High-resolution CT imaging was obtained for treatment planning purposes. Treatment target volumes were identified per the respective institutional guidelines.

PBT was delivered using either a uniform scanning (49 patients, 71%) or a pencil-beam scanning delivery system (20 patients, 29%). In addition, 14 patients (20%) received PBT as a boost combined with photon or neutron therapy. Anterior fields were most typically used. Median PBT dose was 58.5 Gy (RBE; range, 12-78.3; de novo) and 60.0 Gy (RBE; range, 18.2-72.3; re-RT), and median dose per fraction was 2.0 Gy (RBE) for both cohorts disease outcomes for de novo irradiation and reirradiation (re-RT) patients were analyzed separately. The majority of patients were treated with radiation therapy alone. The impact of surgery was not analyzed.

Acute and late toxicities were graded and recorded according to the Common Terminology Criteria for Adverse Events CTCAE version 4.0.

Statistical analysis {#sec2.1}
--------------------

Kaplan-Meier survival curves were calculated for overall survival (OS), freedom from distant metastasis (FFDM), freedom from disease progression (FFDP), and freedom from locoregional recurrence (FFLR). Survival curves were calculated separately for patients receiving de novo irradiation and re-RT. All statistical hypothesis tests were 2-sided; *P* values \< .05 were considered to be statistically significant. Differences in survival curves were compared using the log-rank test. All analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC). OS was defined from the day of initiation of PBT to the date of death or censored at last follow-up. FFDP was defined as from the day of initiation of PBT to the first day of confirmation of recurrent disease whether local, regional, or metastatic. FFLR was defined as any recurrence within the radiation fields or regional lymph nodes. All other recurrences were cataloged as distant failure.

Results {#sec3}
=======

The median follow-up for surviving patients was 26.4 months (range, 3.5-220.5 months). Patient and treatment characteristics for de novo patients and re-RT patients are summarized in [Table 1](#tbl1){ref-type="table"}. In the de novo cohort, 13 patients (31%) had surgical resection before PBT. All but 3 of these patients had a gross total resection. In the re-RT cohort, 13 patients (48%) had surgical resection before PBT. All but 2 of these patients had a gross total resection.

The 3 year OS, FFDM, FFDP, and FFLR are shown for patients who have received de novo irradiation ([Fig 1](#fig1){ref-type="fig"}) and those who have received re-RT ([Fig 2](#fig2){ref-type="fig"}). These outcomes are also shown for de novo irradiation ([Fig 3](#fig3){ref-type="fig"}) and re-RT ([Fig 4](#fig4){ref-type="fig"}) based on SCC histology.Figure 1Kaplan-Meier estimates of overall survival, freedom from distant metastasis, freedom from disease progression, and freedom from locoregional recurrence in patients receiving de novo irradiation.Figure 2Kaplan-Meier estimates of overall survival, freedom from distant metastasis, freedom from disease progression, and freedom from locoregional recurrence in patients receiving reirradiation.Figure 3Kaplan-Meier estimates of overall survival, freedom from distant metastasis, freedom from disease progression, and freedom from locoregional recurrence in patients receiving de novo irradiation with squamous cell carcinoma histology.Figure 4Kaplan-Meier estimates of overall survival, freedom from distant metastasis, freedom from disease progression, and freedom from locoregional recurrence in patients receiving reirradiation with squamous cell carcinoma histology.

On univariate analysis of patients who received de novo irradiation, lymph node involvement was associated with inferior FFLR (*P \< .*01). In patients who received re-RT, SCC histology was associated with inferior OS (*P \< .*01). When directly comparing the de novo irradiation to re-RT cohorts, re-RT was associated with inferior FFLR (*P = .*04).

A total of 12 patients (17.4%) had recurrent disease after PBT ([Table 2](#tbl2){ref-type="table"}). The patient with a regional failure was a Kadish Stage B esthesioneuroblastoma that was initially treated with photon radiation therapy, received PBT for a local recurrence (48.11 GyE in 24 fractions), and subsequently recurred in the neck and distantly. However, the patient is currently alive on last follow-up. Overall, PBT was well tolerated. Three patients (4.3%) required a percutaneous endoscopic gastrostomy tube placed during PBT. There were 11 patients with acute grade 3 toxicities. Acute grade 3 toxicities are summarizing in [Table 3](#tbl3){ref-type="table"}. Late toxicities occurred in 15% of the patients and were limited to grade 1-2 toxicities. There were no grade ≥3 late toxicities. No patients developed vision loss or symptomatic brain necrosis.Table 2Patients with recurrencePatientAgePrimary siteHistologyStagePBT dose (Gy)Re-RTConcurrent chemotherapyType of recurrenceMethod of diagnosing recurrence147Ethmoid sinusSmall cell neuroendocrineIVB70NoCisplatinLocal: Skull basePathologic236Nasal cavitySmall cell neuroendocrineIVB63YesCisplatinLocal: Bilateral ethmoid sinusPathologic362Ethmoid sinusAdenocarcinomaIVA50YesCisplatinLocal: Nasal mucosa and left maxillary sinusPathologic460Nasal cavitySquamous cell carcinomaIVA68YesNoneLocal: Nasal cavityMRI572Nasal cavitySquamous cell carcinomaIVA34YesCetuximabLocal: Nasal cavityUnknown634Maxillary sinusAdenoid cystic carcinomaIVA30YesNoneLocal: Left orbitPhysical exam777Paranasal sinusEsthesioneuroblastomaII48YesNoneRegional and distantPET832Maxillary sinusSquamous cell carcinomaIVB60NoCetuximabDistantMRI954Maxillary sinusAdenoid cystic carcinomaIII60NoCarboplatinDistantPET1056Ethmoid sinusAdenocarcinomaIVA70NoCisplatinDistantMRI1145Paranasal sinusSquamous cell carcinomaIVB65YesNoneDistantMRI1220Nasal CavitySquamous cell carcinomaIVC66NoNoneDistantPET[^3]Table 3Grade 3 acute toxicityGrade 3 acute toxicityNo. of patients (% of *n =* 69)Mucositis8 (11.6%)Pain4 (5.8%)Dermatitis3 (4.3%)Dry mouth2 (2.9%)Dysphagia2 (2.9%)Anorexia2 (2.9%)Conjunctivitis1 (1.4%)Hearing impairment1 (1.4%)Nausea1 (1.4%)

Discussion {#sec4}
==========

Sinonasal tumors are an uncommon and heterogeneous type of head and neck cancer.[@bib1] There are no randomized trials that have evaluated treatment options for sinonasal tumors, thus treatment recommendations have been guided by retrospective, small studies. To our knowledge, this multi-institutional experience is one of the largest reported studies of patients with sinonasal tumors treated with PBT as a component of their radiation therapy. This study demonstrates that PBT seems to be safe in patients with sinonasal tumors.

In our study, the rate of OS, FFLR, FFDP, and FFLR are comparable with the meta-analysis of charged particle therapy versus photon therapy by Patel and colleagues.[@bib16] In addition, primary radiation therapy controlled the overwhelming majority of advanced sinonasal cancer in this cohort. Published series of sinonasal tumors treated with PBT are summarized in [Table 4](#tbl4){ref-type="table"}. Russo et al evaluated the Massachusetts General Hospital experience of sinonasal tumors treated with PBT and reported 2-year overall survival and local control rates of 67% and 80%, respectively.[@bib18] Dagan et al evaluated the University of Florida experience of sinonasal tumors treated with PBT and reported 3-year overall survival and local control rates of 68% and 83%, respectively.[@bib13] Although all patients who received de novo irradiation were alive at 3 years in our study, we acknowledge the limitation of the small number of patients in this cohort. Long-term follow-up is needed to confirm these findings. However, these early results demonstrate that PBT may be an effective treatment option for patients with sinonasal tumors.Table 4Published series of proton beam therapy for sinonasal tumorsAuthorStudy periodInstitution (country)HistologyNo. of patientsMedian ageRT modalityMedian RT doseMedian follow-up (mo)LC (y)OS (y)Fitzek et al[@bib21]1992-1998Massachusetts General Hospital (US)ENB, NEC1944Proton + photon69.2 Gy4588% (5)74% (5)2002Weber et al[@bib22]1991-2001Massachusetts General Hospital (US)SCC, ACC, ENB, PNET, sarcoma, TCC, SNUC, teratocarcinoma3654Proton + photon69.6 Gy52.477.4% (3)[†](#tbl4fndagger){ref-type="table-fn"}90.4% (3)200673.1 (5)[†](#tbl4fndagger){ref-type="table-fn"}80.8% (5)Truong et al[@bib23]1991-2005Massachusetts General Hospital (United States)SCC, ACC, NEC Adeno2053Proton76 Gy2786% (2)53% (2)200931% (2)[†](#tbl4fndagger){ref-type="table-fn"}Zenda et al[@bib24]1999-2006National Cancer Center Hospital East (Japan)SCC, mucosal melanoma, ACC, ENB, SNUC3957Proton65 Gy45.477% (1)59% (3)2011Fukumitsu et al[@bib25]2001-2007University of Tsukuba (Japan)SCC, Adeno, ACC, SNUC, MCC1762Proton78 GyE2335% (2)47.1% (2)201217.5% (5)15.7% (5)Okano et al[@bib26]2006-2012National Cancer Center Hospital East (Japan)SCC, Adeno, SNUC, ENB, small cell carcinoma1347Proton65 GyE56.533.8 (5)[†](#tbl4fndagger){ref-type="table-fn"}75.5% (5)2012Herr et al[@bib27]1997-2013Massachusetts General Hospital (US)ENB2246Proton66.5 GyE7386.4% (5)[†](#tbl4fndagger){ref-type="table-fn"}95.2% (5)2014Demizu et al[@bib28]2003-2011Hyogo Ion Beam Medical Center (Japan)Mucosal melanoma6271Proton, Carbon Ion65 GyE1893% (1)93% (1)200978% (2)61% (2)Fuji et al[@bib29]2006-2010Shizuoka Cancer Center Hospital (Japan)Mucosal melanoma2074Proton70 GyE3562% (5)51% (5)201438% (5)[†](#tbl4fndagger){ref-type="table-fn"}Patel et al[@bib16] Review1990-2014N/ASCC, ACC, Adeno, ENB, other21259IMRT61.4 Gy4034 (5)[∗](#tbl4fnlowast){ref-type="table-fn"}45 (5)201412458Proton60.1 GyE3855 (5)[∗](#tbl4fnlowast){ref-type="table-fn"}70 (5)Russo et al[@bib18]1991-2008Massachusetts General Hospital (US)SCC5456Proton72.8 GyE8280% (2)67% (2)201680% (5)47% (5)Dagan et al[@bib13]2007-2013University of Florida (US)ENB, SCC, ACC, Adeno, SNUC, NEC, mucoepidermoid carcinoma8459Proton + photon73.8 GyE28.883% (3)68% (3)201673% (3)[†](#tbl4fndagger){ref-type="table-fn"}Toyomasu et al[@bib30]2001-2012Hyogo Ion Beam Medical Center (Japan)SCC5960Proton, Carbon Ion67.6 GyE3054% (3)56.2% (3)201850.4% (5)41.6% (5)Present study2010-2016Proton Collaborative GroupSCC, ACC, ENB, Adeno, small cell, SNUC6955.9Proton, photon, neutron53.8 GyE26.492.9% (3)100% (3)58.1 (Re-RT)54.5 GyE (Re-RT)33.8% (3 Re-RT)76% (3 Re-RT)[^4][^5][^6]

The predominant pattern of failure has been demonstrated to be local recurrence. The University of Florida experience reported that local recurrence accounted for 60.7% of the failures.[@bib13] Russo et al also reported a predominantly local recurrence pattern in sinonasal SCC.[@bib18] Our study demonstrates that locoregional recurrence is a significant component of disease progression. Historically, local control in sinonasal malignancies has been demonstrated to be one of the most significant factors for overall disease control. Our study indicates that recurrent disease requiring re-RT is independently a poor prognostic factor in terms of locoregional control. In addition, re-RT patients with SCC had an inferior overall survival when compared with other histologies, an expected finding considering SCC is considered a higher risk histology in sinonasal tumors. Although not statistically significant, patients with SCC in the University of Florida experience also had the worst 3-year overall survival rate when compared with other histologies.[@bib13]

PBT was well tolerated in our study and seems to have favorable toxicities compared with prior photon reports. No patients in our study experienced vision loss or symptomatic brain necrosis. Although there were no documented grade ≥3 late toxicities, the toxicity data was potentially underreported in our cohort. These results should be interpreted with caution especially in the re-RT setting. Demizu et al reported a 9.6% rate of optic neuropathy with charged particle therapy.[@bib28] Particularly for sinonasal tumors, PBT allows for increased target coverage and dose escalation with simultaneous maximal sparing of healthy tissue. PBT has further theoretical advantages over IMRT, including an ability to deposit an increased biologic effective dose to a target with almost no exit dose. Conventional photon radiation therapy is limited by the dose that can be safely administered without harming adjacent optic structures. Jiang et al reported vision loss from radiation-induced optic neuropathy in 8.1% of patients treated with photon radiation therapy.[@bib31] Advances in IMRT have improved clinical outcomes in terms of long-term ocular toxicity.[@bib32] Although it seems that the rate of optic neuropathy with PBT is comparable to photon therapy, reported series of patients who are treated with PBT likely represent an inherently complex cohort of sinonasal tumors. Nevertheless, PBT has been reported to have at least comparable long-term toxicities when directly compared with conventional photon therapy.

This study has several limitations. This is a retrospective series of a group of a heterogeneous group of malignancies with a relatively short follow-up period. Although all patients received curative intent PBT, there was heterogeneity within the treatment regimen. PBT was delivered with varying techniques, and patients who were treated with combined proton and photon therapy were included in the analysis. Thus, this is not purely a charged particle study. In addition, the impact of surgery was not analyzed in this study. Toxicities reported in our study may be incomplete due to institutional variability in follow-up protocol and reporting. This limits our ability to draw definitive conclusions. However, this is one of the largest series of patients with sinonasal tumors treated with PBT with limited late toxicities. It is important to recognize that patients with a historically poor prognosis such as SCC and re-RT were included and analyzed in this study.

The PCG multi-institutional registry experience is consistent with prior published series of patients with sinonasal tumors treated with PBT ([Table 4](#tbl4){ref-type="table"}). Our analysis suggests that PBT is safe and efficacious for treatment of sinonasal tumors.

Conclusions {#sec5}
===========

Sinonasal tumors are rare and can be challenging to treat. Charged particle therapy in the form of proton beam therapy is a promising treatment option. Our findings suggest that proton beam therapy may be a safe and efficacious treatment option for patients with sinonasal tumors. This analysis is in concordance with recent published series of patients with sinonasal tumors treated with proton beam therapy.

Preliminary data were presented at Particle Therapy Co-Operative Group (PTCOG) 56 in Japan.
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[^2]: *Abbreviations:* ECOG PS = Eastern Cooperative Oncology Group performance status; SNUC = sinonasal undifferentiated carcinoma.

[^3]: *Abbreviations:* MRI = magnetic resonance imaging; PET = Positron emission tomography.

[^4]: *Abbreviations:* ACC = adenoid cystic carcinoma; Adeno = adenocarcinoma; ENB = esthesioneuroblastoma; MCC = myoepithelial cell carcinoma; NEC = neuroendocrine carcinoma; PNET = primitive neuroectodermal tumor; RT = radiation therapy; SCC = squamous cell carcinoma; SNUC = sinonasal undifferentiated carcinoma; TCC = transitional cell carcinoma.

[^5]: Locoregional control.

[^6]: Disease-free survival.
